

Joan Albert BarberÀ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7884299/publications.pdf>

Version: 2024-02-01

114
papers

10,423
citations

94381

37
h-index

32815

100
g-index

125
all docs

125
docs citations

125
times ranked

9594
citing authors

#	ARTICLE	IF	CITATIONS
1	A New and More Sensitive Method to Integrate the Desaturation Distance Ratio During a 6-Minute Walking Test in Chronic Respiratory Diseases: Physiological Correlates. <i>Archivos De Bronconeumologia</i> , 2022, 58, 188-190.	0.4	3
2	Home Oxygen Monitoring in Patients with Interstitial Lung Disease. <i>Annals of the American Thoracic Society</i> , 2022, 19, 493-497.	1.5	7
3	Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge. <i>Respiratory Research</i> , 2022, 23, 37.	1.4	23
4	Pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension: the Spanish experience. <i>Annals of Cardiothoracic Surgery</i> , 2022, 11, 151-160.	0.6	6
5	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. <i>Scientific Reports</i> , 2022, 12, 5289.	1.6	6
6	[Translated article] Exercise Tolerance in Pulmonary Hypertension. <i>Archivos De Bronconeumologia</i> , 2022, , .	0.4	0
7	Differences and Similarities between the Lung Transcriptomic Profiles of COVID-19, COPD, and IPF Patients: A Meta-Analysis Study of Pathophysiological Signaling Pathways. <i>Life</i> , 2022, 12, 887.	1.1	0
8	Pulmonary hypertension in chronic obstructive pulmonary disease. <i>British Journal of Pharmacology</i> , 2021, 178, 132-151.	2.7	51
9	Chronic thromboembolic pulmonary hypertension in Spain: a decade of change. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 384-392.	0.4	6
10	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
11	Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 407-415.	1.4	41
12	Protein network analyses of pulmonary endothelial cells in chronic thromboembolic pulmonary hypertension. <i>Scientific Reports</i> , 2021, 11, 5583.	1.6	10
13	The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression. <i>Cells</i> , 2021, 10, 737.	1.8	13
14	Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database. <i>Pulmonary Circulation</i> , 2021, 11, 1-7.	0.8	13
15	Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge. <i>Archivos De Bronconeumologia</i> , 2021, 57, 59-61.	0.4	36
16	Effect of pulmonary hypertension on exercise tolerance in patients with COPD: a prognostic systematic review and meta-analysis. <i>European Respiratory Review</i> , 2021, 30, 200321.	3.0	22
17	Hipertensi3n pulmonar tromboemb3lica cr3nica en Espa3a: una3 cada de cambio. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 384-392.	0.6	9
18	Circulating Cell Biomarkers in Pulmonary Arterial Hypertension: Relationship with Clinical Heterogeneity and Therapeutic Response. <i>Cells</i> , 2021, 10, 1688.	1.8	8

#	ARTICLE	IF	CITATIONS
19	Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension. <i>Scientific Reports</i> , 2021, 11, 18797.	1.6	9
20	Tolerancia al esfuerzo en la hipertensi3n pulmonar. <i>Archivos De Bronconeumologia</i> , 2021, 58, 388-388.	0.4	0
21	An imported case of e-cigarette or vaping associated lung injury in Barcelona. <i>European Respiratory Journal</i> , 2020, 55, 1902076.	3.1	23
22	Decreased Glycolysis as Metabolic Fingerprint of Endothelial Cells in Chronic Thromboembolic Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 710-713.	1.4	5
23	<p>Association Between Systemic and Pulmonary Vascular Dysfunction in COPD</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2037-2047.	0.9	14
24	Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. <i>BMC Pulmonary Medicine</i> , 2020, 20, 154.	0.8	1
25	Pulmonary chronic thromboembolic disease. <i>Archivos De Bronconeumologia</i> , 2020, 56, 314-321.	0.4	2
26	Design of the 123-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial. <i>JACC Basic To Translational Science</i> , 2020, 5, 317-327.	1.9	12
27	<p>Updated Perspectives on Pulmonary Hypertension in COPD</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1315-1324.	0.9	43
28	Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2020, 9, 448.	1.0	20
29	Controversies in the Management of Pulmonary Hypertension in the Setting of Lung Disease. <i>Respiratory Medicine</i> , 2020, , 109-122.	0.1	0
30	Pulmonary vascular density: comparison of findings on computed tomography imaging with histology. <i>European Respiratory Journal</i> , 2019, 54, 1900370.	3.1	47
31	EARLY COPD: determinantes de la aparici3n y progresi3n de la enfermedad pulmonar obstructiva cr3nica en adultos j3venes. Protocolo de un estudio caso-control con seguimiento. <i>Archivos De Bronconeumologia</i> , 2019, 55, 312-318.	0.4	8
32	Progenitor cell mobilisation and recruitment in pulmonary arteries in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2019, 20, 74.	1.4	7
33	Genetic linkage analysis of a large family identifies <i>FIGN</i> as a candidate modulator of reduced penetrance in heritable pulmonary arterial hypertension. <i>Journal of Medical Genetics</i> , 2019, 56, 481-490.	1.5	3
34	Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 194-202.	0.3	19
35	Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study. <i>Basic Research in Cardiology</i> , 2019, 114, 5.	2.5	16
36	Gu3a de diagn3stico y tratamiento de la hipertensi3n pulmonar: resumen de recomendaciones. <i>Archivos De Bronconeumologia</i> , 2018, 54, 205-215.	0.4	26

#	ARTICLE	IF	CITATIONS
37	Instrumental drift removal in GC-MS data for breath analysis: the short-term and long-term temporal validation of putative biomarkers for COPD. <i>Journal of Breath Research</i> , 2018, 12, 036007.	1.5	8
38	Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. <i>Archivos De Bronconeumologia</i> , 2018, 54, 205-215.	0.4	30
39	Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1410-1417.	0.3	15
40	Imbalance between endothelial damage and repair capacity in chronic obstructive pulmonary disease. <i>PLoS ONE</i> , 2018, 13, e0195724.	1.1	27
41	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1000-1011.	2.5	111
42	Metabolic Alterations in Cardiopulmonary Vascular Dysfunction. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 120.	1.6	20
43	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1219-1227.	0.5	135
44	Effect of targeted therapy on circulating progenitor cells in precapillary pulmonary hypertension. <i>International Journal of Cardiology</i> , 2017, 228, 238-243.	0.8	9
45	An official European Respiratory Society statement: pulmonary haemodynamics during exercise. <i>European Respiratory Journal</i> , 2017, 50, 1700578.	3.1	222
46	Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. <i>BMC Pulmonary Medicine</i> , 2017, 17, 216.	0.8	23
47	Slug Is Increased in Vascular Remodeling and Induces a Smooth Muscle Cell Proliferative Phenotype. <i>PLoS ONE</i> , 2016, 11, e0159460.	1.1	11
48	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 894-901.	5.2	59
49	Pulmonary vasculature in COPD: The silent component. <i>Respirology</i> , 2016, 21, 984-994.	1.3	67
50	Persistence of Breakage in Specific Chromosome Bands 6 Years after Acute Exposure to Oil. <i>PLoS ONE</i> , 2016, 11, e0159404.	1.1	8
51	Non-anaemic iron deficiency impairs response to pulmonary rehabilitation in COPD. <i>Respirology</i> , 2015, 20, 1089-1095.	1.3	40
52	Gaining insights into pulmonary hypertension in respiratory diseases. <i>European Respiratory Journal</i> , 2015, 46, 1247-1250.	3.1	8
53	Pulmonary hemodynamic profile in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015, 10, 1313.	0.9	56
54	Management of Pulmonary Hypertension in Patients with Chronic Lung Disease. <i>Current Hypertension Reports</i> , 2015, 17, 62.	1.5	13

#	ARTICLE	IF	CITATIONS
55	Gene and Protein Expression of Fibronectin and Tenascin-C in Lung Samples from COPD Patients. <i>Lung</i> , 2015, 193, 335-343.	1.4	4
56	Follow-Up Genotoxic Study: Chromosome Damage Two and Six Years after Exposure to the Prestige Oil Spill. <i>PLoS ONE</i> , 2015, 10, e0132413.	1.1	14
57	Transdifferentiation of endothelial cells to smooth muscle cells play an important role in vascular remodelling. <i>American Journal of Stem Cells</i> , 2015, 4, 13-21.	0.4	30
58	Circulating Progenitor Cells and Vascular Dysfunction in Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2014, 9, e106163.	1.1	43
59	Pulmonary Hypertension Is Related to Peripheral Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 791-798.	1.6	51
60	Medical and Surgical Management for Chronic Thromboembolic Pulmonary Hypertension: A Single Center Experience. <i>Archivos De Bronconeumologia</i> , 2014, 50, 521-527.	0.4	5
61	Determinants of exercise capacity in obese and non-obese COPD patients. <i>Respiratory Medicine</i> , 2014, 108, 745-751.	1.3	24
62	Tratamiento médico y quirúrgico de la hipertensión pulmonar tromboembólica crónica: experiencia en un único centro. <i>Archivos De Bronconeumologia</i> , 2014, 50, 521-527.	0.4	16
63	La investigación clínica en hipertensión pulmonar ha alcanzado la mayor edad. <i>Archivos De Bronconeumologia</i> , 2014, 50, 463-464.	0.4	0
64	Clinical Research in Pulmonary Hypertension Comes of Age. <i>Archivos De Bronconeumologia</i> , 2014, 50, 463-464.	0.4	0
65	Evaluation of the persistence of functional and biological respiratory health effects in clean-up workers 6years after the Prestige oil spill. <i>Environment International</i> , 2014, 62, 72-77.	4.8	23
66	Pulmonary Hypertension Due to Left Heart Diseases. <i>Journal of the American College of Cardiology</i> , 2013, 62, D100-D108.	1.2	541
67	Pulmonary Hypertension in Chronic Lung Diseases. <i>Journal of the American College of Cardiology</i> , 2013, 62, D109-D116.	1.2	518
68	Chronic Obstructive Pulmonary Disease: A Disease of the Endothelium?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 5-7.	2.5	8
69	Pulmonary vascular abnormalities in chronic obstructive pulmonary disease undergoing lung transplant. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 1262-1269.	0.3	26
70	Hipertensión arterial pulmonar en un paciente con telangiectasia hemorrágica hereditaria. <i>Archivos De Bronconeumologia</i> , 2013, 49, 119-121.	0.4	7
71	Calidad de vida relacionada con la salud en una cohorte nacional de pacientes con hipertensión arterial pulmonar o hipertensión pulmonar tromboembólica crónica. <i>Archivos De Bronconeumologia</i> , 2013, 49, 181-188.	0.4	38
72	Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. <i>European Respiratory Journal</i> , 2013, 42, 982-992.	3.1	149

#	ARTICLE	IF	CITATIONS
73	Echocardiographic abnormalities in patients with COPD at their first hospital admission. <i>European Respiratory Journal</i> , 2013, 41, 784-791.	3.1	95
74	Mechanisms of Development of Chronic Obstructive Pulmonary Disease-Associated Pulmonary Hypertension. <i>Pulmonary Circulation</i> , 2013, 3, 160-164.	0.8	63
75	Chromosomal Bands Affected by Acute Oil Exposure and DNA Repair Errors. <i>PLoS ONE</i> , 2013, 8, e81276.	1.1	8
76	Survival in pulmonary hypertension in Spain: insights from the Spanish registry. <i>European Respiratory Journal</i> , 2012, 40, 596-603.	3.1	342
77	Pulmonary Inflammatory Reaction and Structural Changes Induced by Cigarette Smoke Exposure in the Guinea Pig. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012, 9, 473-484.	0.7	20
78	Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?. <i>Clinical Rheumatology</i> , 2012, 31, 1047-1050.	1.0	39
79	Effects of Cigarette Smoke and Chronic Hypoxia on Ventilation in Guinea Pigs. <i>Clinical Significance. Advances in Experimental Medicine and Biology</i> , 2012, 758, 325-332.	0.8	2
80	Health Effects of Oil Spills: Lessons from the <i>Prestige</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1094-1096.	2.5	10
81	Similar gene expression profiles in smokers and patients with moderate COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011, 24, 32-41.	1.1	44
82	Below What FEV1 Should Arterial Blood be Routinely Taken to Detect Chronic Respiratory Failure in COPD?. <i>Archivos De Bronconeumologia</i> , 2011, 47, 325-329.	0.4	8
83	Effects of cigarette smoke and chronic hypoxia on airways remodeling and resistance. <i>Clinical significance. Respiratory Physiology and Neurobiology</i> , 2011, 179, 305-313.	0.7	20
84	¿Cuál es el mejor FEV1 para detectar insuficiencia respiratoria crónica en la EPOC estable?. <i>Archivos De Bronconeumologia</i> , 2011, 47, 325-329.	0.4	6
85	Vascular Progenitor Cells in Chronic Obstructive Pulmonary Disease. <i>Proceedings of the American Thoracic Society</i> , 2011, 8, 528-534.	3.5	11
86	Should We Administer Sildenafil to Patients with Obstructive Pulmonary Disease and Pulmonary Hypertension? No. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1206-1207.	2.5	0
87	Health Changes in Fishermen 2 Years After Clean-up of the Prestige Oil Spill. <i>Annals of Internal Medicine</i> , 2010, 153, 489.	2.0	68
88	Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. <i>Liver Transplantation</i> , 2010, 16, 348-356.	1.3	65
89	Cigarette Smoke-induced Oxidative Stress. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 477-488.	2.5	233
90	Hemodynamic and Gas Exchange Effects of Sildenafil in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 270-278.	2.5	257

#	ARTICLE	IF	CITATIONS
91	Study of the BMPR2 Gene in Patients with Pulmonary Arterial Hypertension. Archivos De Bronconeumologia, 2010, 46, 129-134.	0.4	2
92	Pulmonary Complications of Abdominal Disease. , 2010, , 1982-1998.		2
93	Ventilation-perfusion imbalance and chronic obstructive pulmonary disease staging severity. Journal of Applied Physiology, 2009, 106, 1902-1908.	1.2	165
94	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537.	1.0	3,108
95	Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S85-S96.	1.2	353
96	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. Revista Espanola De Cardiologia (English Ed), 2009, 62, 1464.e1-1464.e58.	0.4	2
97	Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease. Drugs, 2009, 69, 1153-1171.	4.9	102
98	Effects of cigarette smoke on endothelial function of pulmonary arteries in the guinea pig. Respiratory Research, 2009, 10, 76.	1.4	75
99	Respuesta. Revista Espanola De Cardiologia, 2009, 62, 103-104.	0.6	0
100	Clinical Assessment of Peripheral Muscle Function in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Physical Medicine and Rehabilitation, 2009, 88, 39-46.	0.7	40
101	Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Archivos De Bronconeumologia, 2008, 44, 271-281.	0.4	143
102	Estándares asistenciales en hipertensión pulmonar. Revista Espanola De Cardiologia, 2008, 61, 170-184.	0.6	26
103	Standards of Care in Pulmonary Hypertension. Archivos De Bronconeumologia, 2008, 44, 87-99.	0.4	8
104	Joint Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT) on the Diagnosis and Management of Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2008, 44, 271-281.	0.4	12
105	Pulmonary Vascular Involvement in COPD. Chest, 2008, 134, 808-814.	0.4	225
106	Gas Exchange Response to Short-Acting β_2 -Agonists in Chronic Obstructive Pulmonary Disease Severe Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 350-355.	2.5	24
107	Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension. Liver Transplantation, 2007, 13, 1506-1514.	1.3	26
108	Encouraged 6-min Walking Test Indicates Maximum Sustainable Exercise in COPD Patients. Chest, 2005, 128, 55-61.	0.4	123

#	ARTICLE	IF	CITATIONS
109	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. European Heart Journal, 2004, 25, 2243-2278.	1.0	903
110	Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology, 2003, 38, 452-459.	3.6	73
111	Pulmonary hypertension in chronic obstructive pulmonary disease. European Respiratory Journal, 2003, 21, 892-905.	3.1	371
112	Hepatopulmonary syndrome associated with cardiorespiratory disease. Journal of Hepatology, 1999, 30, 882-889.	1.8	103
113	Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome. Journal of Hepatology, 1999, 31, 1075-1079.	1.8	56
114	Effect of intravenously Administered Aminophylline on Ventilation/Perfusion Inequality during Recovery from Exacerbations of Chronic Obstructive Pulmonary Disease. The American Review of Respiratory Disease, 1992, 145, 1328-1333.	2.9	32